CagriSema — a combination of semaglutide and cagrilintide — reduced the inflammation marker hsCRP by nearly 70% in REDEFINE 1 trial data. Blood pressure dropped approximately 11 mmHg. Retatrutide, a triple-agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, produced nearly 29% weight loss in trials. Survodutide is targeting liver fibrosis with promising early results. And orforglipron — already approved — opens the small-molecule era of GLP-1 therapy.
The pipeline drugs arriving in 2026-2028 will make today's GLP-1 telehealth market look like the dial-up internet era of weight loss treatment.
CagriSema: The Combination Approach
CagriSema pairs semaglutide (a GLP-1 agonist) with cagrilintide (an amylin analog) in a single injection. The rationale is complementary mechanism: semaglutide works through GLP-1 pathways to suppress appetite and slow gastric emptying, while cagrilintide acts on amylin receptors in the brain to enhance satiety signaling through a different neurological pathway.
The REDEFINE 1 data that's generating the most excitement isn't actually the weight loss numbers — it's the cardiovascular and inflammatory data. A nearly 70% reduction in hsCRP (C-reactive protein, a key marker of systemic inflammation) is extraordinary. For context, statins — the gold standard of cardiovascular risk reduction — typically reduce hsCRP by 15-30%. An 11 mmHg blood pressure reduction is clinically meaningful — comparable to what you'd expect from a dedicated blood pressure medication.
These data points suggest that the next generation of GLP-1 combinations may be more accurately described as systemic anti-inflammatory therapies that happen to cause weight loss, rather than weight loss drugs that happen to reduce inflammation.
Retatrutide: The Triple Agonist
If current GLP-1 medications hit one receptor and tirzepatide hits two, retatrutide hits three. Eli Lilly's triple agonist targets GLP-1, GIP, and glucagon receptors simultaneously. The phase 2 trial data showed approximately 29% weight loss — the highest recorded for any anti-obesity medication in clinical trials.
To put 29% in context: the standard Wegovy 2.4mg produces about 15% weight loss. The new Wegovy HD 7.2mg produces about 21%. Tirzepatide produces about 20-22%. Retatrutide at 29% represents a roughly 40% improvement over even the best currently available single-drug results.
Phase 3 trials are underway, with FDA submission expected in 2027-2028 if results hold. If approved, retatrutide would likely be available through the same telehealth channels that currently distribute semaglutide and tirzepatide.
Survodutide: The Liver Play
Boehringer Ingelheim's survodutide targets GLP-1 and glucagon receptors with a specific focus on metabolic-associated steatotic liver disease (MASLD, formerly NAFLD) — a condition affecting roughly 25-30% of adults globally. Early trial data shows significant improvements in liver fibrosis markers alongside meaningful weight loss.
This matters because liver disease is one of the most common and quietly devastating consequences of obesity. Many GLP-1 patients have some degree of fatty liver disease without knowing it. A medication that addresses both obesity and liver fibrosis simultaneously could become the standard of care for patients with metabolic syndrome.
What This Means for Telehealth
The telehealth platforms that survive the 2026 regulatory shakeout will be the ones positioned to prescribe next-generation compounds as they arrive. This requires clinical infrastructure beyond simple prescribing: monitoring capabilities, lab integration, multi-drug management, and prescriber expertise that extends beyond semaglutide.
For patients choosing a telehealth provider today, this pipeline is relevant to your decision. You're not just choosing a platform for your current prescription — you're choosing the clinical relationship that will manage your treatment as the drug landscape evolves. A platform that can only prescribe compounded semaglutide today has no pathway to prescribe CagriSema, retatrutide, or survodutide when they arrive.